Clinical Trials Browser

Phase 1 × INDUSTRY × darinaparsin × Clear all

NCT01435863 2015-08-13

A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL)

Phase 1 Completed

Lymphoma, T-Cell, Peripheral

NCT01689220 2014-09-04

A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) in Korea

Phase 1 Completed

Lymphoma, T-Cell, Peripheral

NCT00591396 2012-07-19

A Phase I Trial of ZIO-101 in Solid Tumors

Phase 1 Completed

Other solid neoplasm

Solid Tumors

NCT00591422 2012-07-19

Phase I Study of Oral Darinaparsin (ZIO-101-C)in Advanced Solid Tumors and Non-Hodgkin's Lymphomas

Phase 1 Unknown

Neoplasms

NCT00592046 2012-07-19

A Phase I Trial of ZIO-101 in Hematologic Cancers

Phase 1 Completed

Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Refractory, with Excess of Blasts, Leukemia, Lymphoma, Multiple Myeloma, Myeloproliferative Disorders, Recurrence, Hematologic Neoplasms

NCT00592163 2012-07-19

Phase I Study of Oral ZIO-101-C in Advanced Solid Tumors and Lymphomas

Phase 1 Unknown

Lymphoma, Neoplasms

NCT01139346 2012-07-19

Study of Oral Darinaparsin in Patients With Advanced Solid Tumors

Phase 1 Completed

Carcinoma, Neoplasm Metastasis, Sarcoma

NCT01139359 2012-07-19

Safety Study of Darinaparsin in Combination With Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) to Treat Lymphoma

Phase 1 Withdrawn

Lymphoma